Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy

JCO Oncol Pract. 2024 Dec 3:OP2400443. doi: 10.1200/OP.24.00443. Online ahead of print.

Authors

Ken Surprenant¹, Lindsay Murray¹, Karen Merritt¹, Maria Hopkins¹, Joanne McIntyre¹

Affiliation

¹ Ken Surprenant, MA, Advocates for Universal DPD/DPYD Testing, Battle Creek, MI; Lindsay Murray, HS, Advocates for Universal DPD/DPYD Testing, Andover, MA; Karen Merritt, BS, Advocates for Universal DPD/DPYD Testing, Chelan, WA; Maria Hopkins, BS, Advocates for Universal DPD/DPYD Testing, Battle Creek, MI; and Joanne McIntyre, AA, Advocates for Universal DPD/DPYD Testing, Portland, OR.

PMID: 39626133
DOI: 10.1200/OP.24.00443

Abstract

Patients, not physicians, should decide if DPYD screening is right for them before FU/Xeloda chemotherapy.

Publication types

Letter